Grail, a Hong Kong-US oncology diagnostics company, announced a $300 million C financing. Since early 2016, Grail has raised over $1.5 billion. The company is sequencing large populations of people — some with cancer, some without — to discover an early blood-based diagnostic test for cancer. Grail was spun out of Illumina, the gene sequencing company. Ally Bridge Group led the financing. Hillhouse Capital and 6 Dimensions Capital co-led the round. In 2017, Grail merged with Cirina, a Hong Kong cancer diagnostics company, which was co-founded by Dennis Lo, DM, DPhil, an early scientific leader in the field of molecular diagnostics.
Source: China Biotoday
